Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000164752 | SCV000215426 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-08-29 | criteria provided, single submitter | clinical testing | The p.V849L variant (also known as c.2545G>T), located in coding exon 10 of the BRCA2 gene, results from a G to T substitution at nucleotide position 2545. The valine at codon 849 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001824650 | SCV002074170 | uncertain significance | not specified | 2022-01-10 | criteria provided, single submitter | clinical testing | |
University of Washington Department of Laboratory Medicine, |
RCV000164752 | SCV003848400 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |